







Министерство за здравство на Република Македонија

КАМПАЊА ЗА РАЦИОНАЛНА УПОТРЕБА НА АНТИБИОТИЦИ

ANTIMICROBIAL RESISTANCE IN MACEDONIA COMPARED WITH BALKAN REGION AND EUROPE: RESULTS OF CAESAR NETWORK

Ass Prof Dr Golubinka Bosevska **AMR focal point** Institute of Public Health of R. Macedonia

Bangkok, 29 January 2018





Министерство за здравство на Република Македонија

"Golden age of antibiotics"

- Fleming, Nobel Lecture, December 11, 1945 -"The time may come when penicillin can be bought by anyone in the shops. Then there is the danger that the ignorant man may easily underdose himself and by exposing his microbes to non-lethal quantities of the drug make them resistant.
- Although with best intention still ongoing:
 - Easy access and availability
 - Irrational prescribing
 - Misuse





Antibiotic resistance – when bacteria change and cause antibiotics to fail – is happening **RIGHT NOW,** across the world

The full impact is unknown. There is no system in place to track antibiotic resistance globally



Without urgent action, many modern medicines could become obsolete, turning even common infections into deadly threats.

A GROWING CRISIS WORLDWIDE

In the EUROPEAN UNION, antibiotic resistance causes 25,000 deaths per year and 2.5m extra hospital days'













Министерство за здравство на Република Македонија

AMR – global threat

"Antimicrobial resistance is increasingly widespread in the WHO European Region as resistant microbes know no borders.

Effective infection prevention and control is one of our most powerful weapons to address this global health threat."



Dr Zsuzsanna Jakab WHO Regional Director for Europe










Министерство за здравство на Република Македонија

AMR and actions in R. Macedonia

"If you cannot measure it, you cannot improve it"



Lord Kelvin, 1824-1907







Министерство за здравство на Република Македонија

AMR and actions in R. Macedonia



- November 2008 Awareness campaign
- 06.05.2009 Multisectorial commission for surveillance of antimicrobial resistance established
- WHO partnership
- 26.04.2011– Goverment of RM adopted National strategy with action plan for control of antimicrobial resistance in RM 2012-2016







Министерство за здравство на Република Македонија

National strategy with action plan for control of antimicrobial resistance in RM 2012-2016

- 1. Information and education of patients and general population
- 2. Strengthening the surveillance system and control of AMR and consumption of antimicrobials
- 3. Use of control and preventive measures to support prudent use of antimicrobials
- 4. Continuous education and training of health professionals







Министерство за здравство на Република Македонија

НА АНТИБИОТИЦИ Central Asian and Eastern European Surveillance of Antimicrobial Resistance (CAESAR)

- Microorganisms:
 - S. aureus (MRSA)
 - <mark>- Str. pneumoniae (Pe</mark>n R)

КАМПАЊА

- E. coli (ESBL+, carbapenemase +)

ЗА РАЦИОНАЛНА УПОТРЕБА

- K. pneum. (ESBL +, carbapenemase +)
- *E. faecium* и faecalis (VRE)
- Ps. aeruginosa (multiresistant)
- Acinetobater spp.
- Susceptibility test results of invasive isolates (blood and CSF) - per patient per quarter
- International standards EUCAST/CLSI





Министерство за здравство на Република Македонија

CAESAR annual reports

2017 report

- 9 reporting countries vs 7 in 2016
- Updated maps of AMR in the whole European region, joint with EARS-Net (ECDC)
- Progress in CAESAR network countries

•http://www.euro.who.int/en/health-topics/disease-prevention/antimicrobialresistance/publications/2017/central-asian-and-eastern-european-surveillance-ofantimicrobial-resistancecaesar.-annual-report-2017













Министерство за здравство на Република Македонија

Progress in CAESAR network countries

Since 2016:

- More national AMR reference laboratories in place
- 2 more countries provided national data (Georgia and Montenegro)
- Data quality improved from level B to level A in 2 countries (Bosnia and Herzegovina and Serbia)
- One more pathogen under surveillance added (Salmonella)
- Participation in external quality assessment increased and results improved







Министерство за здравство на Република Македонија

WHO Global AMR surveillance system (GLASS)

Sample	Priority pathogens	-Patients in the hospitals and in the				
blood	E. coli K. pneumoniae A. baumannii S. aureus S. pneumoniae Salmonella spp	community - continuous -Macedonia join to				
urine	E. coli K. pneumoniae	GLASS in 2017				
faeces	Salmonella spp. Shigella spp. Clostridium diff.					
Urethral and cervical swabs	N. gonorrhoeae					







Министерство за здравство на Република Македонија

Total number of isolates and % of resistance – Limitation – evidence level B

2013 2014 2015 2016	S. aureus	Str. pneumon.	Ent. faecalis	Ent. faecium	E. coli	Kl. pneumon.	Acinetobacter	P. aeruginosa
Total number	225	28	88	56	226	121	110	42
Resistance	MRSA	PNSP	VRE	VRE	ESBL	ESBL	CRAB	CRPA
% of resistance	48	30	1,7	65	73	85,6	84	36,0








Министерство за здравство на Република Македонија

Third generation cephalosporin resistant E. coli



Level B data: the data provide an indication of the resistance patterns present in clinical settings in the country or area, but the proportion of resistance should be interpreted with care. Improvements are needed to attain a more valid assessment of the magnitude and trends of AMR in the country or area. For more information about levels of evidence, see section 4.2 Levels of evidence are only provided for CAESAR countries and areas.

EARS-Net countries: Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, the Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, United Kingdom.

CAESAR countries and areas: Albania, Armenia, Azerbaijan, Belarus, Bosnia and Herzegovina, Georgia, Kazakhstan, Kyrgyzstan, Montenegro, the Republic of Moldova, the Russian Federation, Serbia, Switzerland, Tajikistan, The former Yugoslav Republic of Macedonia, Turkey, Turkmenistan, Ukraine, Uzbekistan and Kosovo (in accordance with United Nations Security Council resolution 1244 (1999))








Министерство за здравство на Република Македонија

Carbapenem resistant E. coli



Level B data: the data provide an indication of the resistance patterns present in clinical settings in the country or area, but the proportion of resistance should be interpreted with care. Improvements are needed to attain a more valid assessment of the magnitude and trends of AMR in the country or area. For more information about levels of evidence, see section 4.2 Levels of evidence are only provided for CAESAR countries and areas.

EARS-Net countries: Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, the Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, United Kingdom.

CAESAR countries and areas: Albania, Armenia, Azerbaijan, Belarus, Bosnia and Herzegovina, Georgia, Kazakhstan, Kyrgyzstan, Montenegro, the Republic of Moldova, the Russian Federation, Serbia, Switzerland, Tajikistan, The former Yugoslav Republic of Macedonia, Turkey, Turkmenistan, Ukraine, Uzbekistan and Kosovo (in accordance with United Nations Security Council resolution 1244 (1999))








Министерство за здравство на Република Македонија

Multidrug-resistant (combined resistance to third-generation cephalosporins, fluoroquinolones and aminoglycosides) *K. pneumoniae*



Level B data: the data provide an indication of the resistance patterns present in clinical settings in the country or area, but the proportion of resistance should be interpreted with care. Improvements are needed to attain a more valid assessment of the magnitude and trends of AMR in the country or area. For more information about levels of evidence, see section 4.2 Levels of evidence are only provided for CAESAR countries and areas.

EARS-Net countries: Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, the Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, United Kingdom.

CAESAR countries and areas: Albania, Armenia, Azerbaijan, Belarus, Bosnia and Herzegovina, Georgia, Kazakhstan, Kyrgyzstan, Montenegro, the Republic of Moldova, the Russian Federation, Serbia, Switzerland, Tajikistan, The former Yugoslav Republic of Macedonia, Turkey, Turkmenistan, Ukraine, Uzbekistan and Kosovo (in accordance with United Nations Security Council resolution 1244 (1999))








Министерство за здравство на Република Македонија

Carbapenem resistant K. pneumoniae



Level B data: the data provide an indication of the resistance patterns present in clinical settings in the country or area, but the proportion of resistance should be interpreted with care. Improvements are needed to attain a more valid assessment of the magnitude and trends of AMR in the country or area. For more information about levels of evidence, see section 4.2 Levels of evidence are only provided for CAESAR countries and areas.

EARS-Net countries: Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, the Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, United Kingdom.

CAESAR countries and areas: Albania, Armenia, Azerbaijan, Belarus, Bosnia and Herzegovina, Georgia, Kazakhstan, Kyrgyzstan, Montenegro, the Republic of Moldova, the Russian Federation, Serbia, Switzerland, Tajikistan, The former Yugoslav Republic of Macedonia, Turkey, Turkmenistan, Ukraine, Uzbekistan and Kosovo (in accordance with United Nations Security Council resolution 1244 (1999))








Министерство за здравство на Република Македонија

Multidrug-resistant (combined resistance to fluoroquinolones, aminoglycosides and carbapenems) *Acinetobacter spp.*



Level B data: the data provide an indication of the resistance patterns present in clinical settings in the country or area, but the proportion of resistance should be interpreted with care. Improvements are needed to attain a more valid assessment of the magnitude and trends of AMR in the country or area. For more information about levels of evidence, see section 4.2 Levels of evidence are only provided for CAESAR countries and areas.

EARS-Net countries: Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, the Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, United Kingdom.

CAESAR countries and areas: Albania, Armenia, Azerbaijan, Belarus, Bosnia and Herzegovina, Georgia, Kazakhstan, Kyrgyzstan, Montenegro, the Republic of Moldova, the Russian Federation, Serbia, Switzerland, Tajikistan, The former Yugoslav Republic of Macedonia, Turkey, Turkmenistan, Ukraine, Uzbekistan and Kosovo (in accordance with United Nations Security Council resolution 1244 (1999))



<1% 1% to <5% 5% to <10% 10% to <25% 25% to <50% ≥50%

Not included % Level B data

Luxembourg Malta


КАМПАЊА ЗА РАЦИОНАЛНА УПОТРЕБА НА АНТИБИОТИЦИ





Министерство за здравство на Република Македонија

MRSA in Europe



Level B data: the data provide an indication of the resistance patterns present in clinical settings in the country or area, but the proportion of resistance should be interpreted with care. Improvements are needed to attain a more valid assessment of the magnitude and trends of AMR in the country or area. For more information about levels of evidence, see section 4.2 Levels of evidence are only provided for CAESAR countries and areas.

EARS-Net countries: Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, the Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, United Kingdom.

CAESAR countries and areas: Albania, Armenia, Azerbaijan, Belarus, Bosnia and Herzegovina, Georgia, Kazakhstan, Kyrgyzstan, Montenegro, the Republic of Moldova, the Russian Federation, Serbia, Switzerland, Taijkistan. The former Yugoslav Republic of Macedonia, Turkey, Turkmenistan, Ukraine, Uzbekistan and Kosovo (in accordance with United Nations Security Council resolution 1244 (1999))



кампања за рационална употреба на антибиотици Conclusion





Министерство за здравство на Република Македонија

- Significant increase in third-generation cephalosporin resistance of E.coli
- Emergence of carbapenem resistant E. coli!!!!
- Multidrug-resistant *K. pneumoniae* has become common in the European Region
- High proportions of multidrug resistance and carbapenem resistance K. pneumoniae and multidrug-resistant Acinetobacter spp - reflect the dissemination of resistant clones in the health care settings and indicate the serious limitation in treatment options
- Increasing levels of community-associated MRSA



кампања за рационална употреба на антибиотици Conclusion





Министерство за здравство на Република Македонија

- Support countries that are building or strengthening their national AMR surveillance
- Stimulate development of early warning system in case of MDR strain and rapid sharing information/data between countries
- Providing timely AMR data is critical for policy decisions and rapid actions – national, regional and international







Министерство за здравство на Република Македонија

A coordinated response is urgently needed



Nobody is exempt from the problem nor
from playing a part in the solution»

(WHO Global Strategy for Containment of Antimicrobial Resistance)



КАМПАЊА ЗА РАЦИОНАЛНА УПОТРЕБА Министерство за здравство на Република Македонија Acknowledgement





- **1**.Ministry of Health
- 2. Institute of Public Health
- 3. WHO Europe ٠
- 4. WHO office Skopje ٠
- 5. Medical faculty Skopje Institute of microbiology and parasitology ٠
- 6.. Health Insurance fund ۰
- 7. Macedonian medical agency
- 8. Macedonian Microbiological Society
- 9. Macedonian association for control of intrahospital infections
- 10. Faculty of veterinary medicine
- 11. Food and veterinary agency
- 12. Center for regional policy and research Studiorum
- 13. Mayor of the city Shtip ۰
- 14. Microbiological laboratories
- 15. Center for family medicine
- 16. Medical faculty Shtip .